A Pilot Trial to Assess Potential Effects of Selective Intracoronary Bone Marrow-Derived Progenitor Cell Infusion in Patients with Non-Ischemic Dilated Cardiomyopathy: Final 1-Year Results of the TOPCARE-DCM Trial
نویسندگان
چکیده
Background Intracoronary administration of bone marrow-derived progenitor cells (BMC) was shown to improve coronary microvascular function in ischemic heart disease. Since coronary microvascular dysfunction is implicated in the pathogenesis and prognosis of non-ischemic dilated cardiomyopathy (DCM), we investigated the effects of intracoronary BMC administration in patients with DCM. Methods and Results Intracoronary infusion of BMC was performed in 33 patients with DCM by an over-the-wire balloon catheter. Left ventricular (LV) contractility at baseline and after three months was assessed by analysis of LV angiograms. Coronary hemodynamics were determined by intracoronary Doppler wire measurements. After three months, regional wall motion of the target area (contractility from -1.08±0.39 to -0.97±0.47 SD/chord, p=0.029) and global LV ejection fraction (from 30.2±10.9 to 33.4±11.5 %, p<0.001) were improved. Increase of regional contractile function was directly related to the functionality of the infused cells as measured by their colony forming capacity. Minimal vascular resistance index was significantly reduced in the BMC-treated vessel after three months (from 1.53±0.63 to 1.32±0.61 mmHg*s/cm; p=0.002, n=24), whereas no changes were observed in the reference vessel (from 1.60±0.45 to 1.49±0.45 mmHg*s/cm; p=0.133, n=13). 12 months after BMC infusion, NT-proBNP serum levels were decreased suggesting a beneficial effect on LV remodeling processes (from 1610±993 to 1473±1147 pg/ml; p=0.038 for logNT-proBNP, n=26). Conclusions Intracoronary administration of BMC appears to be associated with improvements in cardiac contractile and microvascular function in patients with DCM. Thus, randomized blinded studies are warranted to evaluate potential clinical benefits of intracoronary BMC administration in patients with DCM.
منابع مشابه
A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy.
BACKGROUND Intracoronary administration of bone marrow-derived progenitor cells (BMC) was shown to improve coronary microvascular function in ischemic heart disease. Because coronary microvascular dysfunction is implicated in the pathogenesis and prognosis of nonischemic dilated cardiomyopathy (DCM), we investigated the effects of intracoronary BMC administration in patients with DCM. METHODS...
متن کاملRandomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial.
AIMS The REGENERATE-DCM trial is the first phase II randomized, placebo-controlled trial aiming to assess if granulocyte colony-stimulating factor (G-CSF) administration with or without adjunctive intracoronary (IC) delivery of autologous bone marrow-derived cells (BMCs) improves global left ventricular (LV) function in patients with dilated cardiomyopathy (DCM) and significant cardiac dysfunct...
متن کاملIntramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy.
BACKGROUND AIMS Mesenchymal stromal cells (MSC) may improve cardiac function following myocardial infarction. MSC can differentiate into cardiomyocytes and endothelial cells while exerting additional paracrine effects. There is limited information regarding the efficacy of route for MSC treatment of severe dilated cardiomyopathy (DCM). The aim of this study was to demonstrate the clinical safet...
متن کاملTransplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial.
OBJECTIVES The Transplantation of Progenitor Cells And Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) trial investigates both safety, feasibility, and potential effects on parameters of myocardial function of intracoronary infusion of either circulating progenitor cells (CPC) or bone marrow-derived progenitor cells (BMC) in patients with acute myocardial infarction (AMI)....
متن کاملThe REPAIR-AMI and ASTAMI trials: cell isolation procedures.
10 The time between myocar-dial infarction and intracoronary infusion therapy was nearly identical in the BMC and placebo group (median of 4 days), thus any spontaneous improvement in left ventri-cular ejection fraction (LVEF) prior to intra-coronary infusion therapy may have occurred to the same extent in both groups. As suggested by Marenzi and Bartor-elli, we re-analysed a potential effect o...
متن کامل